MedPath

DIAbetes-PREvention Trial.

Suspended
Conditions
Coronary artery disease (CAD): PCI or CABG in stable CAD, or post STEMI and post non-STEMI, Cardiac rehabilitation , Diabetes Mellitus
Registration Number
NL-OMON21355
Lead Sponsor
Isala Klinieken, te ZwolleMaatschap Cardiologie, Interne en sportgeneeskunde, Isala Klinieken.
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
Not specified
Target Recruitment
78
Inclusion Criteria

1. Pcoronary artery disease (CAD): PCI or CABG in stable CAD, or post STEMI and post non-STEMI (inclusion within 2 month after admission);

2. Age ≥ 18 years;

Exclusion Criteria

1. Known diabetics, with or without anti-diabetic medication;

2. Contra-indications for Metformine use as stated in the medication registration;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
A 10% reduction in HbA1c at one year in patients with coronary artery disease (PCI or CABG in stable CAD, or post STEMI and post non-STEMI patients) that have pre-diabetes.
Secondary Outcome Measures
NameTimeMethod
1. hsCRP;<br /><br>2. LDL cholesterol;<br /><br>3. MACE at one year FUP;<br /><br>4. Exercise capacity.
© Copyright 2025. All Rights Reserved by MedPath